MD, PhD, Adjunct professor Maija Itälä-Remes - UTU Tutkimustietojärjestelmä

Maija Itälä-Remes
MD, PhD, Adjunct professor

- professori,
sisätautioppi (kliininen laitos)

maija.itala@utu.fi

	Curriculum.pdf
	Publications Full.pdf

Asiantuntijuusalueet

hematologia; akuutti leukemia; kantasolujensiirto

Biografia

Academic degrees:

Medical doctor 26.5.1986, University of Turku, Finland
Doctoral thesis (”B-cell Chronic Lymphocytic Leukemia and Increased Susceptibility to Infections”) and 13.9.1996, University of Turku
Doctorate, PhD 4.12.1997, University of Turku
Adjunct professor Internal Medicine/Clinical Haematology 18.4.2005, University of Turku

Professional appointments:

Resident/specialist in Internal Medicine and in Anaesthesia 1986-1997 Turku University Central Hospital.
Clinical haematologist, Turku University Central Hospital 1997-2007.
Medical Adviser, Janssen-Cilag, Nordic Section 2007-2008.
Head of Department of Haematology, Tampere University Central Hospital 2008-2010.
Head of Stem Cell Transplant Unit, Turku University Hospital 2010-2017.
Head of Stem Cell Transplant Unit, Helsinki University Hospital 2017-2018.
Head of Division of Clinical Haematology and Stem Cell Transplant Unit, Programme Director of Stem Cell Transplant Unit, Turku University Central Hospital 2018-

Dissertations:

Supervisor 3, Opponent 2, Reviewer 4

Other academic appontments:

Review of the scientific work for docent application

Appointments in Scientific Societies:

Chair of the Finnish Society of Haematology 2012-2014, member 2014-.
Chair of the Finnish Acute Leukemia Working Group 2015-2018, member 2018-
The Nordic-Dutch Working Group for CLL (Chronic Lymphocytic Leukemia) Group, member 2000-2014.
The Finnish Haematology Registry and Biobank, member of the Steering group 2012-2014.
The European Group for Blood and Marrow Transplantation, member 1997-

Duties with National Authorities:

Consultant of the Parliament (Implementation of EU directives into National legislation) 2006-2007
Consultant of the Ministry of Social Affairs and Health (STM) 2016
Consultant of the Finnish Medicine Agency (Fimea) 2016-2018
EU consultation Brussels 2017

Activities in Quality Management:

Inspector exam of FACT/JACIE Quality Management System 31.5.2011, Rotterdam.
Establishment of the Quality Management System of the Stem Cell Unit of Turku University Hospital 2006; Moderation of initial JACIE accreditation and two re-accreditations 2006-2017 Turku University Central Hospital, Turku.

Tutkimus

Scientific publications and text book articles in field of stem cell transplantions and haematological malignancies

Principal Investigator and Sub-investigator of International Multicentre Clinical Trials

GCP training, latest update 22.2.2018

Opetus

Lectures at Finnish University Hospitals and Central Hospitals

Public lectures

Lectures at International meetings

Education of residents and junior colleagues (Clinical haematology and Stem Cell Transplantations)

Member of Faculty of the International Congress on Stem Cell Transplantation and Cellular Therapies, Berlin 2017

Julkaisut

4/4

Anti-Thymocyte Globulin Improves Survival Free From Relapse and Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis by the Acute Leukemia Working Party of the EBMT (2018)
- Cancer
Czerw T, Labopin M, Giebel S, Socie G, Volin L, Fegueux N, Masszi T, Blaise D, Chaganti S, Cornelissen JJ, Passweg J, Maertens J, Itala-Remes M, Wu D, Mohty M, Nagler A
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT (2018)
- PLoS ONE
Juha Ranti, Samu Kurki, Urpu Salmenniemi, Mervi Putkonen, Soile Salomäki, Maija Itälä-Remes
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Hidden genomic MHC disparity between HLA-amtched sibling pairs in hematopoietic stem cell transplantation (2018)
- Scientific Reports
Koskela S, Ritari J, Hyvärinen K, Kwan T, Niittyvuopio R, Itälä-Remes M, Pastinen T, Partanen J.
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety (2018)
- Molecular therapy. Methods & clinical development
Joni Keto, Tanja Kaartinen, Urpu Salmenniemi, Johanna Castrén, Jukka Partanen, Arno Hänninen, Matti Korhonen, Kaarina Lähteenmäki, Maija Itälä-Remes, Johanna Nystedt
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT (2018)
- Haematologica
Nico Gagelmann, Diderik-Jan Eikema, Simona Iacobelli, Linda Koster, Hareth Nahi, Anne-Marie Stoppa, Tamás Masszi, Denis Caillot, Stig Lenhoff, Miklos Udvardy, Charles Crawley, William Arcese, Clara Mariette, Ann Hunter, Xavier Leleu, Martin Schipperus, Michel Delforge, Pietro Pioltelli, John A. Snowden, Maija Itälä-Remes, Maurizio Musso, Anja van Biezen, Laurent Garderet, Nicolaus Kröger
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT (2018)
- British Journal of Haematology
Donal P. McLornan, Richard Szydlo, Marie Robin, Anja van Biezen, Linda Koster, Henrik J. P. Blok, Maria T. Van Lint, Jürgen Finke, Antonin Vitek, Kristina Carlson, Laimonas Griskevicius, Ernst Holler, Maija Itälä-Remes, Michel Schaap, Gerard Socié, Jacques-Olivier Bay, Yves Beguin, Benedetto Bruno, Jan J. Cornelissen, Tobias Gedde-Dahl, Per Ljungman, Marie T. Rubio, Ibrahim Yakoub-Agha, Evgeny Klyuchnikov, Eduardo Olavarria, Yves Chalandon, Nicolaus Kröger
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä)
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT (2018)
- Journal of Hematology and Oncology
Annalisa Ruggeri, Myriam Labopin, Andrea Bacigalupo, Boris Afanasyev, Jan J. Cornelissen, Ahmet Elmaagacli, Maija Itälä-Remes, Didier Blaise, Ellen Meijer, Yener Koc, Noel Milpied, Harry C. Schouten, Nicolaus Kroeger, Mohamad Mohty, Arnon Nagler
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol - a prospective nationwide study (2017)
- Infectious Diseases
Kolonen A, Sinisalo M, Huttunen R, Syrjanen J, Aittoniemi J, Huhtala H, Sankelo M, Rintala H, Raty R, Jantunen E, Nousiainen T, Saily M, Kauppila M, Itala-Remes M, Ollikainen H, Rauhala A, Koistinen P, Elonen E
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Good responses but high TRM in adult patients after MSC therapy for GvHD (2017)
- Bone Marrow Transplantation
Salmenniemi U, Itälä-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, Korhonen M
(B1 Vertaisarvioimaton kirjoitus tieteellisessä lehdessä )
Immunomonitoring of patients treated with mesenchymal stromal cells for steroid-refractory severe graft-versus-host disease (2017)
- Cytotherapy
Keto J, Kaartinen T, Salmenniemi U, Partanen J, Hanninen A, Lahteenmaki K, Korhonen M, Itala-Remes M, Nystedt J
(O2 Muu julkaisu )
Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (2017)
- Journal of Clinical Oncology
Martinez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, Itala-Remes M, Bermudez A, Forcade E, Russo D, Potter M, McQuaker G, Yakoub-Agha I, Scheid C, Bloor A, Montoto S, Dreger P, Sureda A
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia (2017)
- Leukemia and Lymphoma
Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van t' Veer MB, Tjonnfjord GE, Itala-Remesg MA, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, Van Oers MHJ, Geisler CH, Niemann CU
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia (2017)
- Leukemia and Lymphoma
Vojdeman FJ, van't Veer MB, Tjonnfjord GE, Itala-Remes M, Kimby E, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, van Oers MHJ, Geisler CH
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party (2017)
- Bone Marrow Transplantation
Scheid C, de Wreede L, van Biezen A, Koenecke C, Gohring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, Itala-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Espiga CR, Peniket A, Sierra J, Mufti G, Crawley C, Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kroger N
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
A Prospective Randomized Trial Comparing Cyclosporine/Methotrexate And Tacrolimus/Sirolimus As Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation (2016)
- Haematologica
Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, Itälä-Remes M, Remberger M, Mattsson J
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML (2016)
- Frontiers in Immunology
Impola U, Larjo A, Salmenniemi U, Putkonen M, Itala-Remes M, Partanen J
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Immunomonitoring of patients treated with mesenchymal stromal cells for graft versus host disease: a case study (2016)
- Scandinavian Journal of Immunology
Keto J, Kaartinen T, Salmenniemi U, Partanen J, Hanninen A, Lahteenmaki K, Korhonen M, Itala-Remes M, Nystedt J
(O2 Muu julkaisu )
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL (2014)
- Blood
Geisler CH, vant' Veer MB, Jurlander J, Walewski J, Tjonnfjord G, Remes MI, Kimby E, Kozak T, Polliack A, Wu KL, Wittebol S, Abrahamse-Testroote MCJ, Doorduijn J, Alemayehu WG, van Oers MHJ
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR (2008)
- European Journal of Haematology
Itälä, Maija; Huhtinen, Anna-Riina; Juvonen, Vesa; Kairisto, Veli; Pelliniemi, Tarja-Terttu; Penttilä, Tarja-Leena; Rauhala, Auvo; Tienhaara, Anri; Remes, Kari
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )